Shares of GW Pharma (NASDAQ:GWPH) were up 16% on potentially exciting news regarding its drug Epidiolex for patients suffering from treatment-resistant epilepsy. The study in question had 27 patients, 15% of whom were seizure-free after 12 weeks of treatment. There was also an impressive 44% mean overall reduction in seizure frequency.
Nonetheless, it's important for investors to remember that this was a tiny, non-placebo controlled trial, so it's hard to draw too many conclusions yet.
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson talk about Epidiolex and GW's opportunities moving forward.